These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Balsalazide plus high-potency probiotic preparation (VSL[sharp]3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon. Tursi A J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S119-22. PubMed ID: 18806701 [TBL] [Abstract][Full Text] [Related]
4. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Tursi A; Brandimarte G; Giorgetti GM; Forti G; Modeo ME; Gigliobianco A Med Sci Monit; 2004 Nov; 10(11):PI126-31. PubMed ID: 15507864 [TBL] [Abstract][Full Text] [Related]
6. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Tursi A; Brandimarte G; Papa A; Giglio A; Elisei W; Giorgetti GM; Forti G; Morini S; Hassan C; Pistoia MA; Modeo ME; Rodino' S; D'Amico T; Sebkova L; Sacca' N; Di Giulio E; Luzza F; Imeneo M; Larussa T; Di Rosa S; Annese V; Danese S; Gasbarrini A Am J Gastroenterol; 2010 Oct; 105(10):2218-27. PubMed ID: 20517305 [TBL] [Abstract][Full Text] [Related]
7. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gionchetti P; Rizzello F; Venturi A; Brigidi P; Matteuzzi D; Bazzocchi G; Poggioli G; Miglioli M; Campieri M Gastroenterology; 2000 Aug; 119(2):305-9. PubMed ID: 10930365 [TBL] [Abstract][Full Text] [Related]
8. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Venturi A; Gionchetti P; Rizzello F; Johansson R; Zucconi E; Brigidi P; Matteuzzi D; Campieri M Aliment Pharmacol Ther; 1999 Aug; 13(8):1103-8. PubMed ID: 10468688 [TBL] [Abstract][Full Text] [Related]
9. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Miele E; Pascarella F; Giannetti E; Quaglietta L; Baldassano RN; Staiano A Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792 [TBL] [Abstract][Full Text] [Related]
10. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Kühbacher T; Ott SJ; Helwig U; Mimura T; Rizzello F; Kleessen B; Gionchetti P; Blaut M; Campieri M; Fölsch UR; Kamm MA; Schreiber S Gut; 2006 Jun; 55(6):833-41. PubMed ID: 16401690 [TBL] [Abstract][Full Text] [Related]
11. Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis. Dang X; Xu M; Liu D; Zhou D; Yang W PLoS One; 2020; 15(3):e0228846. PubMed ID: 32182248 [TBL] [Abstract][Full Text] [Related]
12. The current place of probiotics and prebiotics in the treatment of pouchitis. Lichtenstein L; Avni-Biron I; Ben-Bassat O Best Pract Res Clin Gastroenterol; 2016 Feb; 30(1):73-80. PubMed ID: 27048898 [TBL] [Abstract][Full Text] [Related]
13. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Holubar SD; Cima RR; Sandborn WJ; Pardi DS Cochrane Database Syst Rev; 2010 Jun; (6):CD001176. PubMed ID: 20556748 [TBL] [Abstract][Full Text] [Related]
14. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. Shen J; Zuo ZX; Mao AP Inflamm Bowel Dis; 2014 Jan; 20(1):21-35. PubMed ID: 24280877 [TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of antibiotics and probiotics in the treatment of pouchitis. Gionchetti P; Calabrese C; Lauri A; Rizzello F Expert Rev Gastroenterol Hepatol; 2015; 9(9):1175-81. PubMed ID: 26202437 [TBL] [Abstract][Full Text] [Related]
16. Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going? Naseer M; Poola S; Ali S; Samiullah S; Tahan V Curr Clin Pharmacol; 2020; 15(3):216-233. PubMed ID: 32164516 [TBL] [Abstract][Full Text] [Related]
17. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gionchetti P; Rizzello F; Helwig U; Venturi A; Lammers KM; Brigidi P; Vitali B; Poggioli G; Miglioli M; Campieri M Gastroenterology; 2003 May; 124(5):1202-9. PubMed ID: 12730861 [TBL] [Abstract][Full Text] [Related]
18. High-dose probiotics for the treatment of active pouchitis. Gionchetti P; Rizzello F; Morselli C; Poggioli G; Tambasco R; Calabrese C; Brigidi P; Vitali B; Straforini G; Campieri M Dis Colon Rectum; 2007 Dec; 50(12):2075-82; discussion 2082-4. PubMed ID: 17934776 [TBL] [Abstract][Full Text] [Related]
19. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Mimura T; Rizzello F; Helwig U; Poggioli G; Schreiber S; Talbot IC; Nicholls RJ; Gionchetti P; Campieri M; Kamm MA Gut; 2004 Jan; 53(1):108-14. PubMed ID: 14684584 [TBL] [Abstract][Full Text] [Related]
20. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Pronio A; Montesani C; Butteroni C; Vecchione S; Mumolo G; Vestri A; Vitolo D; Boirivant M Inflamm Bowel Dis; 2008 May; 14(5):662-8. PubMed ID: 18240282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]